INIFY LABORATORIES AB (WY60) - Net Assets
Based on the latest financial reports, INIFY LABORATORIES AB (WY60) has net assets worth €181.64 Million EUR (≈ $212.35 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€204.64 Million ≈ $239.25 Million USD) and total liabilities (€23.00 Million ≈ $26.89 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read debt load of INIFY LABORATORIES AB for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €181.64 Million |
| % of Total Assets | 88.76% |
| Annual Growth Rate | 282.24% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 11946.02 |
INIFY LABORATORIES AB - Net Assets Trend (2021–2025)
This chart illustrates how INIFY LABORATORIES AB's net assets have evolved over time, based on quarterly financial data. Also explore WY60 total assets for the complete picture of this company's asset base.
Annual Net Assets for INIFY LABORATORIES AB (2021–2025)
The table below shows the annual net assets of INIFY LABORATORIES AB from 2021 to 2025. For live valuation and market cap data, see INIFY LABORATORIES AB stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €106.54 Million ≈ $124.55 Million |
+218.94% |
| 2024-12-31 | €33.40 Million ≈ $39.05 Million |
-60.72% |
| 2023-12-31 | €85.05 Million ≈ $99.43 Million |
-38.54% |
| 2022-12-31 | €138.37 Million ≈ $161.77 Million |
+27626.88% |
| 2021-12-31 | €499.05K ≈ $583.44K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to INIFY LABORATORIES AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 18633905000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €292.88 Million | 274.91% |
| Total Equity | €106.54 Million | 100.00% |
INIFY LABORATORIES AB Competitors by Market Cap
The table below lists competitors of INIFY LABORATORIES AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
HOYA Resort Hotel Group
TWO:2736
|
$30.74 Million |
|
GLOBUS MARITIME DL -004
F:0G93
|
$30.74 Million |
|
In The F
KO:014990
|
$30.74 Million |
|
WT Financial Group Ltd
AU:WTL
|
$30.75 Million |
|
Heramed Ltd
AU:HMD
|
$30.73 Million |
|
Qingdao Hengshun Zhongsheng
SHE:300208
|
$30.71 Million |
|
Petrolia SE
F:0PE
|
$30.70 Million |
|
Eldav-L
TA:ELDAV
|
$30.70 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in INIFY LABORATORIES AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 33,403,000 to 106,537,000, a change of 73,134,000 (218.9%).
- Net loss of 67,886,000 reduced equity.
- New share issuances of 141,602,000 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-67.89 Million | -63.72% |
| Share Issuances | €141.60 Million | +132.91% |
| Other Changes | €-582.00K | -0.55% |
| Total Change | €- | 218.94% |
Book Value vs Market Value Analysis
This analysis compares INIFY LABORATORIES AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.19x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 23.25x to 0.19x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €0.01 | €0.25 | x |
| 2022-12-31 | €3.01 | €0.25 | x |
| 2023-12-31 | €1.85 | €0.25 | x |
| 2024-12-31 | €0.73 | €0.25 | x |
| 2025-12-31 | €1.33 | €0.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently INIFY LABORATORIES AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -63.72%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -308.49%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 1.32x
- Recent ROE (-63.72%) is above the historical average (-93.68%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2023 | -62.70% | -4469.82% | 0.01x | 1.09x | €-61.83 Million |
| 2024 | -154.61% | -393.29% | 0.31x | 1.28x | €-54.98 Million |
| 2025 | -63.72% | -308.49% | 0.16x | 1.32x | €-78.54 Million |
Industry Comparison
This section compares INIFY LABORATORIES AB's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $3,395,410,609
- Average return on equity (ROE) among peers: -67.96%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| INIFY LABORATORIES AB (WY60) | €181.64 Million | -62.70% | 0.13x | $30.74 Million |
| IZOTROPIC CORP. (1R3) | $-4.86 Million | 0.00% | 0.00x | $11.45 Million |
| ALPHAHELIX MOL.DIAGN. SK1 (4MB) | $10.41 Million | -90.99% | 0.83x | $1.06 Million |
| HANGZHOU TIGERMED CO. H 1 (5HZ1) | $24.45 Billion | 8.28% | 0.21x | $500.93 Million |
| Check-Cap Ltd (7CC) | $50.69 Million | -33.94% | 0.10x | $8.64 Million |
| INTERGRATED DIA.H DL 025 (8I8) | $3.10 Billion | 16.46% | 0.86x | $288.34 Million |
| GENETIC ANALYSIS NK -60 (8V8) | $27.08 Million | -42.15% | 0.94x | $2.85 Million |
| GENINCODE PLC LS -01 (9PL) | $1.29 Million | -544.30% | 2.25x | $6.89 Million |
| INOVIQ LTD. (EGQ0) | $19.99 Million | -32.79% | 0.09x | $25.34 Million |
| Eurofins Scientific SE (ESF0) | $4.68 Billion | 16.73% | 1.00x | $11.18 Billion |
| ICON Public Limited Company (IJF) | $1.62 Billion | 23.11% | 0.80x | $7.52 Billion |
About INIFY LABORATORIES AB
INIFY Laboratories AB provides cancer diagnostics services in Sweden. It offers prostate cancer diagnostics services. The company was incorporated in 2021 and is based in Stockholm, Sweden.